Artificial Intelligence

Woman reading on a tablet
#2023 #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Biotech hubs #Cell and gene therapy #CRISPR #Diversity #Oncology #Regulatory

DDW top reads in 2023

DDW’s Senior Digital Content Editor Diana Spencer reviews the year’s top ten articles. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a… Read More

#Exclusive Content

Boston, MA
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Events #Lab technology #SLAS2024

SLAS2024 Ignite Theater: Will you be there?

Make sure you leave time in your SLAS2024 schedule to attend the Ignite Theater track on the theme ‘Innovation & technology: from lab to patient’. The programme, curated by DDW and sponsored by Integra Biosciences and Hamamatsu Corporation, will feature leading research from… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Biosecurity #Federation of American Scientists #Machine learning

Federation of American Scientists addresses biosecurity risks of AI

The Federation of American Scientists (FAS) has published five policy recommendations to address the challenges of artificial intelligence (AI) in life sciences. The Bio X AI policy recommendations address the need for oversight of biodesign AI tools, biosecurity screening of synthetic DNA and guidance on biosecurity… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Events #Lab technology #SLAS2024

Speakers announced for SLAS2024 Ignite Theater: Register now

The line-up of speakers is now confirmed for the SLAS2024 Ignite Theater: ‘Innovation & technology: from lab to patient’, curated by DDW and sponsored by Integra Biosciences and Hamamatsu Corporation. The event will take place on 5 and 6 February 2024 at SLAS in Boston, and will present… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Drug discovery #Generative AI

Can vertical AI advance cell and gene therapies? 

Andrew Busey, Co-Founder, Form Bio, discusses why vertical AI is set to reshape the cell and gene therapy sector. The once-fictional artificial intelligence (AI) depicted in literature and movies has transitioned into a tangible and easily accessible tool in our modern world. General AI tools such as ChatGPT have acted… Read More

#Exclusive Content

Obulytix team
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Artificial intelligence (AI) #Ghent University #Start-ups

University spin-off creates solution to antibiotic resistance

Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The phage lysin-based platform – using artificial intelligence (AI) – has attracted a significant €4 million investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma… Read More

#Business & Investment #News #Start-up Zone

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cloud computing #Drug discovery #Machine learning

Future-proofing drug discovery through flexible platforms

Dr Robert Scoffin, CEO, and Tim Cheeseright, Chief Technology Officer, at Cresset, explore the importance of flexible solutions for future-proofing drug discovery.  The ability to respond to changes in patient and customer needs is a constant challenge in the pharmaceutical industry, with ever-evolving requirements influencing even the earliest stages of… Read More

#Exclusive Content

Ageing hands
#Ageing #Artificial intelligence (AI) #Cancer research #Insilico Medicine #Transcriptomics #University of Chicago #University of Oslo

AI and transcriptomics identify dual targets for ageing and cancer

An international research team is the first to use artificial intelligence (AI) analysis to identify dual-purpose target candidates for the treatment of cancer and ageing. Researchers from the University of Oslo, University of Chicago Pritzker School of Medicine, and Insilico Medicine used Insilico’s AI target discovery… Read More

#Cancer Research #Editor's Choice #News

Lisbon skyline
#Bispecific Antibodies #Immunotherapy #Machine learning #PEGS Europe 2023 #Protein engineering

What to expect from PEGS Europe 2023: Day 3

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against… Read More

#Exclusive Content

Lisbon skyline
#Biotherapeutics #CAR-T #Combination therapy #Drug targets #Engineered antibodies #Machine learning #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 2

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 2, Wednesday 15 November 2023, the tracks include: Engineering antibodies, emerging targets and therapeutic approaches, advancing bispecifics and combination… Read More

#Exclusive Content

AI clinical trials concept
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trial design #Clinical trials

Decoding diseases: The AI renaissance in clinical trials

Listen to this article on the DDW Podcast: Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Over 19 million1 hearts succumb to cardiovascular disease yearly, while around 10 million2 lives are claimed by cancer every year. To put… Read More

#Exclusive Content

Antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Start-ups

Advancing antibody discovery with AI

Listen to this article on the DDW Podcast: DenovAI is the second start-up to launch from the global pharma consortium AION Labs -  an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. DDW Editor Reece Armstrong, speaks to Kashif… Read More

#Exclusive Content #Start-up Zone

Machine learning concept
#Artificial intelligence (AI) #Drug discovery #Machine learning #VeriSIM Life

The impact of AI and ML on the future of drug discovery  

Over the past several years, Dr Jo Varshney, Founder of VeriSIM Life, has front-led numerous collaborative engagements with a host of biopharma companies, government agencies, academic/medical institutes and industry innovators. Here, she discusses with DDW’s Megan Thomas the impact of AI and ML on the drug discovery process.   MT:… Read More

#Exclusive Content #Opinion

#Artificial intelligence (AI) #BioIndustry Association #Machine learning #TechBio #UK

Five UK TechBio companies driving the AI revolution

The UK TechBio sector is thriving, according to a new report, with a growing number of companies pioneering ground-breaking products and services. A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the power of engineering biology,… Read More

#News #Trends & Analysis

#Clinical trials #Deep learning #Immunotherapy #Oncology #Start-ups

New podcast: Drug discovery success stories

This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal… Read More

#News

#Antibody-based therapeutics #Artificial intelligence (AI) #CAR-T #Mergers and acquisitions #Microbiome #Partnership #Proteomics

Drug discovery deals highlight key growth areas

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in… Read More

#Business & Investment #News